Round led by Healthier Capital positions Dandelion to scale its clinical intelligence infrastructure across drug development, trial optimization, and precision medicine.
NEW YORK, May 5, 2026 /PRNewswire-ÌÇÐÄVlog/ -- Dandelion Health, the clinical intelligence platform for life sciences, today announced a $14 million Series A funding round led by Healthier Capital, with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures. The investment will accelerate Dandelion's growth across pharmaceutical drug development, deepening its data infrastructure, expanding its pharma partnerships, and bringing its platform to more research and commercial teams across the industry.
The Dandelion AI platform transforms comprehensive clinical data, collected directly from patients across its hospital network, into novel scientific insights that power the next generation of diagnosis and treatment. Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion is unique in its ability to combine structured data — electronic medical records and claims — with unstructured clinical text and raw biological signals including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound. Together, these sources amount to more than eight petabytes of deeply linked, multimodal patient data. Dandelion's platform has attracted partnerships with leading global pharmaceutical companies and the American Heart Association.
"Most clinical data is never seen, let alone used. ECGs, echocardiograms, radiology scans — these are generated millions of times a day, and they carry signals that no one is systematically capturing at scale. We built Dandelion to change that," said Elliott Green, CEO and Co-Founder of Dandelion Health. "This round lets us go deeper with our pharma partners and demonstrate what's possible when the full richness of a patient's clinical record is actually brought to bear on drug development."
Dandelion's platform spans the full pharmaceutical development lifecycle through three core products. Precision Trial Designer uses real-world patient simulations to optimize clinical trial design, reducing both trial size and duration; Evidence Explorer enables disease trajectory modeling, biomarker discovery, and real-world evidence generation. Biomarker Developer validates AI algorithms against diverse, real-world patient populations.
The platform's impact is already measurable: in a trial emulation with a top-10 pharmaceutical company, Dandelion's multimodal approach delivered projected cost savings of up to $84 million and accelerated timelines by up to 11 months, compared to conventional trial design.
"Dandelion is doing something genuinely different in health data — combining the scale of a large real-world dataset with the depth of raw biological signals that most platforms simply cannot access," said Aman Mahajan MD PhD, Partner, Healthier Capital. "The team's scientific depth and the partners they've drawn in make clear why pharma is turning to Dandelion to make smarter decisions across the drug development lifecycle."
The Series A financing will be used to expand Dandelion's pharmaceutical partnerships, scale the company's data and engineering infrastructure, and grow commercial and scientific teams. In addition to Green, Dandelion's founding team includes Chief Science Officer Ziad Obermeyer, MD, a physician-scientist at Harvard Medical School and the University of California, Berkeley; Sendhil Mullainathan, PhD, an economist at MIT and MacArthur Fellow; and Niyum Gandhi, Chief Financial and Strategy Officer of Mass General Brigham.
About Dandelion Health
Dandelion Health is the clinical intelligence platform for life sciences. The company's multimodal data infrastructure – spanning 73 hospitals, more than 15 million patients, and eight petabytes of structured, unstructured, and raw biological data – powers a platform that helps pharmaceutical companies design smarter trials, discover novel biomarkers, and generate real-world evidence. Dandelion serves partners across the full drug development lifecycle, from discovery through commercialization. The company is headquartered in New York. For more information, visit .
About Healthier Capital
Healthier Capital partners with technology-powered innovators to deliver healthier outcomes for all. The firm was founded by Amir Dan Rubin, former CEO of One Medical, the tech-enabled primary care organization now part of Amazon, and invests in early-stage companies at the intersection of healthcare and technology. For more information, visit .
About Colle Capital
Colle Capital Partners is a global, early-stage technology venture fund with a core focus on data-driven businesses across healthcare, fintech, and logistics. Founded in 2015 and based in New York, Colle Capital partners with agile teams building foundational infrastructure in complex, regulated industries. For more information, visit .
Media Contact
Media Contact
AV Ploumpis, Dandelion Health, 1 201-472-0271, [email protected],
SOURCE Dandelion Health
Share this article